Reduced reliance on "white pill/western markets" helps GSK grow in third quarter
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's CEO Andrew Witty told investors that the UK group's efforts to reduce dependency on what he described as "white pill/western markets" had paid off in the third quarter, with overall sales returning to growth. Total turnover of £6.76 billion was up by 15%, or by 3% when the positive effects of currency exchange rate changes are discounted.